Motif Bio plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Motif Bio plc
Compassionate Use Programs In APAC: China Breaks The Ice
Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities.
Hong Kong's First 2022 Biotech IPO Debuts
One IPO on the Hong Kong Stock Exchange and seven venture capital or private equity deals raised a combined $329m in China in February.
New Trial With Longer Liver Elevation Needed For Iclaprim, US FDA Tells Motif Bio
Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.
Motif Plunges As FDA Demands New Iclaprim Study
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
- Other Names / Subsidiaries
- Amphion Innovations plc
- Motif BioSciences inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.